Allergy - 5: Allergy and the skin: eczema and chronic urticaria


Autoria(s): Katelaris, C. H.; Peake, J. E.
Contribuinte(s)

M. Van Der Weyden

Data(s)

01/11/2006

Resumo

Eczema is common, occurring in 15%-20% of infants and young children. For some infants it can be a severe chronic illness with a major impact on the child's general health and on the family. A minority of children will continue to have eczema as adults. The exact cause of eczema is not clear, but precipitating or aggravating factors may include food allergens (most commonly, egg) or environmental allergens/irritants, climatic conditions, stress. and genetic predisposition. Management of eczema consists of education; avoidance of triggers and allergens; liberal use of emollients or topical steroids to control inflammation; use of antihistamines to reduce itch; and treatment of infection if present. Treatment with systemic agents may be required in severe cases, but must be supervised by an immunologist. Urticaria (hives) may affect up to a quarter of people at some time in their lives. Acute urticaria is more common in children, while chronic urticaria is more common in adults. Chronic urticaria is not life-threatening, but the associated pruritus and unsightly weals can cause patients much distress and significantly affect their daily lives. Angioedema coexists with urticaria in about 50% of patients. It typically affects the lips, eyelids, palms, soles and genitalia. Management of urticaria is through education; avoidance of triggers and allergens (where relevant); use of antihistamines to reduce itch; and short-term use of corticosteroids when antihistamine therapy is ineffective. Referral is indicated for patients with resistant disease.

Identificador

http://espace.library.uq.edu.au/view/UQ:81837

Idioma(s)

eng

Publicador

Australasian Medical Publishing Co

Palavras-Chave #Medicine, General & Internal #Chronic Idiopathic Urticaria #Randomized Controlled-trial #Atopic-dermatitis #Double-blind #Food Hypersensitivity #Thyroid Autoimmunity #Helicobacter-pylori #Children #Impact #Montelukast #C1 #320201 Allergy #320503 Clinical Pharmacology and Therapeutics #321002 Dermatology #730102 Immune system and allergy #730117 Skin and related disorders
Tipo

Journal Article